Image

North America Molecular Point Of Care Testing (using NAAT) Market – Industry Trends and Forecast to 2028

Medical Devices

Image

North America Molecular Point Of Care Testing (using NAAT) Market – Industry Trends and Forecast to 2028

  • Medical Devices
  • Published Report
  • Aug 2022
  • North America
  • 350 Pages
  • No of Tables: 91
  • No of Figures: 42

North America Molecular Point of Care Testing (Using NAAT), By Product (Instruments And Consumables And Reagents), Indication (Respiratory Infections Testing, Sexually Transmitted Infection (STI) Testing, Gastrointestinal Tract Infections Testing And Others), End User ( Laboratories, Hospitals, Clinics, Home Care, Ambulatory Centers, Assisted Living Facilities And Others), Mode Of Testing ( Prescription-Based Testing And OTC-Based Testing), Distribution Channel (Direct Sales, Third Party Distributors, Online Sales), Country (U.S. and Canada), Industry Trends and Forecast to 2028

North America Molecular Point Of Care Testing (using NAAT) Market

Market Analysis and Insights: North America Molecular Point Of Care Testing (using NAAT) Market 

North America molecular point of care testing (using NAAT) market is expected to reach USD 34,736.47 million by 2028, from USD 12,711.40 million in 2020, growing at the CAGR of 12.1% in the forecast period of 2021 to 2028.

POCT is characterized as testing which can be done close to the patient where a medical decision can be made immediately, including the results and monitoring. POCT devices now entering into clinical use are based on nucleic acid amplification technologies (NAAT), defined here as second-generation devices. These platforms generally have improved sensitivity, typically in the range of 60 to 90%, compared to first-generation POCTs, and require portable instrumentation with a footprint of approximately 30cm x 30cm. These instruments are essentially used in the molecular detection of various disorders such as HIV, HPV, and respiratory disease through NAAT technology. NAAT is Nucleic Acid Amplification Techniques which allows identification of pathogenic organisms by detecting their DNA or RNA.

  • In the global pandemic, attempt to synergize the sensitivity of NAATs and the ease of use of POCT assays, miniaturized NAAT-based POCT devices and assays were devised for faster screening and diagnosis of COVID-19, which also propelled the growth of the market.

Molecular point-of-care testing's significant advantages include the rapid diagnosis process, treatment choice, monitoring, and prognosis. This will also help in operational decision-making and proper resource utilization. The increasing prevalence of chronic disease and increasing diagnosis-seeking rate are expected to act as drivers for the market. However, the high cost of POCT instruments may hinder the growth of the market.

The strategic initiatives taken by the major players are anticipated to provide lucrative opportunities for the market's growth. On the other hand, the stringent regulatory approval may act as a challenge for the market

This North America molecular point of care testing (using NAAT) market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

North America Molecular Point Of Care Testing (using NAAT) Market

North America Molecular Point Of Care Testing (using NAAT) Market Scope And Market size

North America molecular point of care testing (using NAAT) market is segmented into five notable segments which are based on product, indication, end user, mode of testing, and distribution channel.

  • On the basis of product, the North America molecular point of care testing (using NAAT) market is segmented into instruments, consumables, and reagents. In 2021, the consumables & reagents segment in the molecular point of care testing (using NAAT) market is expected to grow due to the presence of a wide portfolio for the U.S. population, as there are many companies manufacturing kits and instruments for North America Region.
  • On the basis of indication, the North America molecular point of care testing (using NAAT) market is segmented into a sexually transmitted infection (STI) testing, respiratory infection testing, gastrointestinal tract infection testing, and others. In 2021, the respiratory segment in the molecular point of care testing (using NAAT) market is expected to dominate because of the worse condition of COVID-19 in U.S. population.
  • On the basis of end user, the North America molecular point of care testing (using NAAT) market is segmented into laboratories, hospitals, clinics, ambulatory centers, home care, assisted living facilities, and others. In 2021, the laboratories segment in the molecular point of care testing (using NAAT) market is expected to dominate because of the high quality of diagnosis and research in U.S.
  • On the basis of the mode of testing, the North America molecular point of care testing (using NAAT) market is segmented into prescription-based testing and OTC testing. In 2021, the prescription-based testing segment in the molecular point of care testing (using NAAT) market is expected to grow due to the fact that the use of NAAT in PCOT is new and thus requires expert advice and monitoring which increases the market for prescription-based testing.
  • On the basis of distribution channel, the North America molecular point of care testing (using NAAT) market is segmented into direct tender, third party distributor, online sales. In 2021, direct sales segment in the molecular point of care testing (using NAAT) market is expected to grow due to fact that majority of companies working in this market have their presence in U.S. which increase the direct sales in this region.

North America Molecular Point of Care Testing (Using NAAT) Market Country Level Analysis

The North America molecular point of care testing (using NAAT) market is analyzed, and market size information is provided by product, indication, end user, mode of testing, and distribution channel.

The U.S. is expected to dominate the North America molecular point of care testing (using NAAT) market due to the presence of excellent healthcare infrastructure, which increases the demand for molecular POCT products than other countries in North America region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data. 

New Product Launches By Manufactures is Creating New Opportunities For Players in The Molecular Point of Care Testing (Using NAAT) Market

North America molecular point of care testing (using NAAT) market also provides you with detailed market analysis for every country growth in aesthetic industry with molecular point of care testing (using NAAT) market sales, impact of advancement in the molecular point of care testing (Using NAAT) market and changes in regulatory scenarios with their support for the North America molecular point of care testing (Using NAAT) market. The data is available for the historic period 2010 to 2019. 

Competitive Landscape and Molecular Point of Care Testing (Using NAAT) Market Share Analysis

North America molecular point of care testing (using NAAT) market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to North America molecular point of care testing (using NAAT) market.

The major companies providing North America molecular point of care testing (Using NAAT) products in North America molecular point of care testing (using NAAT) market are Thermo Fisher Scientific Inc., Hologic, Inc., BD, F. Hoffmann-La Roche Ltd, ABBOTT, Seegene Inc., bioMérieux SA, QIAGEN, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Grifols, S.A., Quidel Corporation, GenMark Diagnostics, Inc., SD Biosensor, INC., Oxford Nanopore Technologies, Wondfo, Randox Laboratories Ltd., Meridian Bioscience, Sekisui Diagnostics, QuantuMDx Group Ltd., Lucira Health Inc., binx health, inc., Sysmex (A Subsidiary of Sysmex Corporation), Co-Diagnostics, Inc., among others.

Many product launches and agreements are also initiated by companies worldwide, which are also accelerating the molecular point of care testing (using NAAT) market.

For instance, 

  • In May 2020, Bio-Rad Laboratories, Inc. announced that they had received FDA Emergency Use Authorization (EUA) for the SARS-CoV-2 total Ab test. It is a blood-based immunoassay used to help clinicians identify if an individual has developed antibodies against SARS-CoV-2. After receiving this approval, the company has enhanced its credibility in the market

This new product launched by the company has increased its protein estimation portfolio in the market. Collaboration, joint ventures, and other strategies by the market player are enhancing the company market in the molecular point of care testing (using NAAT) market, which also provides the benefit for the organization to improve their offering for North America molecular point of care testing (Using NAAT) market.


SKU-

TABLE 1 CEPHEID: ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 2 THERMO FISHER SCIENTIFIC INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 3 HOLOGIC, INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 4 BD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 5 F. HOFFMANN-LA ROCHE LTD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 6 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY, 2020 (UNITS)

TABLE 7 DISTRIBUTORS ACROSS NORTH AMERICA

TABLE 8 DISTRIBUTORS ACROSS EUROPE

TABLE 9 DISTRIBUTORS ACROSS SOUTH ASIA

TABLE 10 DISTRIBUTORS ACROSS SOUTH EAST ASIA

TABLE 11 DISTRIBUTORS ACROSS MIDDLE EAST

TABLE 12 DISTRIBUTORS ACROSS AFRICA

TABLE 13 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA CONSUMABLES & REAGENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 NORTH AMERICA INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 NORTH AMERICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 NORTH AMERICA SEXUALLY TRANSMITTED IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 22 NORTH AMERICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 NORTH AMERICA LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA HOSPITAL IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 NORTH AMERICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 32 NORTH AMERICA AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 NORTH AMERICA AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 34 NORTH AMERICA HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 NORTH AMERICA HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 36 NORTH AMERICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 NORTH AMERICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 38 NORTH AMERICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 40 NORTH AMERICA PRESCRIPTION-BASED TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 2019-2028 (USD MILLION)

TABLE 41 NORTH AMERICA OTC TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 43 NORTH AMERICA HOSPITAL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 NORTH AMERICA RETAIL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA ONLINE PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 47 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 48 NORTH AMERICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 49 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 50 NORTH AMERICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 51 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 52 NORTH AMERICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 53 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 54 NORTH AMERICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 55 NORTH AMERICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 56 NORTH AMERICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 57 NORTH AMERICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 58 NORTH AMERICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 59 NORTH AMERICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 60 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 61 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 62 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 63 U.S. INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 64 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 65 U.S. RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 66 U.S. SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 67 U.S. GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 68 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 69 U.S. LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 70 U.S. HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 71 U.S. CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 72 U.S. AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 73 U.S. HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 74 U.S. ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 75 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 76 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 77 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 78 CANADA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 79 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 80 CANADA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 81 CANADA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 82 CANADA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 83 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 84 CANADA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 85 CANADA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 86 CANADA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 87 CANADA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 88 CANADA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 89 CANADA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 90 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 91 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The North America Molecular Point Of Care Testing (using NAAT) Market value is expected USD 34,736.47 million by 2028.
The North America Molecular Point Of Care Testing (using NAAT) Market is to grow at a CAGR of 12.1% during the forecast by 2029.
The major players operating in the North America Molecular Point Of Care Testing (using NAAT) Market are Thermo Fisher Scientific Inc., Hologic, Inc., BD, F. Hoffmann-La Roche Ltd, ABBOTT, Seegene Inc., bioMérieux SA, QIAGEN, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Grifols, S.A., Quidel Corporation, GenMark Diagnostics, Inc., SD Biosensor, INC., Oxford Nanopore Technologies, Wondfo, Randox Laboratories Ltd., Meridian Bioscience, Sekisui Diagnostics, QuantuMDx Group Ltd., Lucira Health Inc., binx health, inc., Sysmex (A Subsidiary of Sysmex Corporation), Co-Diagnostics, Inc., among others.
On the basis of product, the North America Molecular Point Of Care Testing (using NAAT) Market is segmented into Instruments And Consumables And Reagents.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials